Acute myeloid leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis of bone.
The first case of secondary leukemia (FAB M3 microgranular variant) after single-agent chemotherapy with etoposide is described. The peculiar morphology and the absence of previously described cytogenetic abnormalities make this case of interest and emphasize the need for further study of epipodophyllotoxin-related leukemia.
Haupt
R
R
Department of Hematology-Oncology, G. Gaslini Children's Hospital, Genova, Italy.
Comelli
A
A
Rosanda
C
C
Sessarego
M
M
De Bernardi
B
B
D000208:Acute Disease; D001847:Bone Diseases / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D002648:Child; D005047:Etoposide / Q000009:adverse effects*; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced* / Q000235:genetics; D014178:Translocation, Genetic
D005047:Etoposide